Saccharin Salts of Active Pharmaceutical Ingredients, Their Crystal Structures, and Increased Water Solubilities
Source abstract
Abstract
Salts of active pharmaceutical ingredients (APIs) have been traditionally used in drug formulations because of improved properties with respect to solubility, stability, or bioavailability. Saccharin has been used as an acid for salt formation with APIs in a few cases hitherto. In this paper, we have explored the generality of this property and have isolated saccharinates of quinine, haloperidol, mirtazapine, pseudoephedrine, lamivudine, risperidone, sertraline, venlafaxine, zolpidem, and amlodipine. These salts have been characterized with single-crystal X-ray methods. The structures contain many hydrogen bonds of the O−H···N (-), N (+)- H···N (-), N (+) −H···O, N−H···O, O−H···O and N−H···N type, with auxiliary C−H···N (-) and C−H···O interactions. These saccharinates are mostly very soluble in water when compared to the free base. Additionally, aqueous solutions of these API saccharinates are of moderate pH. Both these properties may be advantageous in the pharmaceutical industry. In general, most saccharinates would appear to have high water solubility, and this follows from the molecular structure of the anion, which is donor-poor and acceptor-rich in terms of hydrogen-bonding functionalities. If an API of insufficient basicity is treated with saccharin, it may form a hydrogen-bonded cocrystal wherein proton transfer from saccharin to the API does not take place. This phenomenon was found in the cocrystal saccharin−piroxicam.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Crystallography and molecular interactions · Crystallization and Solubility Studies · Phenothiazines and Benzothiazines Synthesis and Activities
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Chemistry, University of Hyderabad, Hyderabad 500046, India, and Informatics Division, GVK Biosciences Private Limited, 6-3-1192, Begumpet, Hyderabad 500016, India
References (49)
Show source-provided references
1. Byrn S. R. · 1999
2. Brittain H. G. · 1999
3. Dutta S. · Nat. Rev. Drug Discovery · 2004 · 3 · 4210.1038/nrd1280 ↗
4. Morris K. R. · 1993
5. Morissette S. L. · Adv. Drug Delivery Rev. · 2004 · 56 · 27510.1016/j.addr.2003.10.020 ↗
6. Selected · 2002
7. Tremblay J.-F. · Chem. Eng. News · 2005 · 83 · 1510.1021/cen-v083n002.p015 ↗
8. Gu C. H. · 2003
9. (b) Puddipeddi, M.; Serajuddin, A. T. M.; Grant, D. J. W.; Stahl, P. H. InHandbook of Pharmaceutical Salts: Properties, Selection, and Use; Stahl, P. H., Wermuth, C. G., Eds.; Wiley, Weinheim, 2002; pp 19−38.
10. Neau S. · 2000 · 425
11. Berge S. M. · J. Pharm. Sci. · 1977 · 66 · 110.1002/jps.2600660104 ↗
12. Räder, K.; Stoss, P. U.S. publication no., US 4362730, 07/12/1982.
13. Rayburn, J. W. International publication no., WO 00/12067, 09/03/2000.
14. Schwalbe C. H. · Cryst. Rev. · 2005 · 11 · 4910.1080/08893110500078456 ↗
15. Bhatt P. M. · Chem. Commun. · 2005 · 107310.1039/b416137h ↗
16. SMART, Version 5.05; Bruker AXS, Inc. Madison, Wisconsin, 1998.
17. SAINT, Version 6.2, Bruker AXS, Inc. Madison, Wisconsin, 2001.
18. Sheldrick, G. M.SHELXTL V5.1; Madison, WI, 1998.
19. The Rietveld · 2000
20. Glomme A. · J. Pharm. Sci. · 2005 · 94 · 110.1002/jps.20212 ↗
21. Ward, S. C.; Hursthouse, M. B.; Woods, D. C.; Lewis, S. M. Systematic Study into the Salt Formation of Functionalised Organic Substrates,http://www.nesc.ac.uk/events/ahm2003/AHMCD/pdf/040.pdf.
22. Selected · Top. Curr. Chem. · 2005 · 41 · 70
23. Bhogala B. R. · Cryst. Growth Des. · 2005 · 5 · 168310.1021/cg058012p ↗
24. Fleischman S. G. · J. Cryst. Growth Des. · 2003 · 3 · 90910.1021/cg034035x ↗
25. Almarsson · J. Chem. Commun. · 2004 · 188910.1039/b402150a ↗
26. Seeman P. · Nature · 1976 · 261 · 71710.1038/261717a0 ↗
27. Kanfer I. · Pharmacotherapy · 1993 · 13 · 116S10.1002/j.1875-9114.1993.tb02780.x ↗
28. van Leeuwen R. · J. Infect. Dis. · 1995 · 171 · 116610.1093/infdis/171.5.1166 ↗
29. Grant S. · Drugs · 1994 · 48 · 25310.2165/00003495-199448020-00009 ↗
30. Cohen L. · J. Pharmacotherapy · 1994 · 14 · 25310.1002/j.1875-9114.1994.tb02819.x ↗
31. Peeters O. M. · J. Acta Crystallogr., Sect. C. · 1993 · 49 · 169810.1107/S0108270193002240 ↗
32. Murdoch D. · Drugs · 1992 · 44 · 60410.2165/00003495-199244040-00007 ↗
33. Koe B. K. · J. Pharmacol. Exp. Ther. · 1983 · 226 · 686
34. Clerc G. E. · Int. Clin. Psychopharmacol. · 1994 · 9 · 13910.1097/00004850-199409000-00001 ↗
35. Oosterbaan, M. J. M.; Keltjens, R. International publication no., U.S. 20030190353 A1, 09/10/2003.
36. Langtry H. D. · Drugs · 1990 · 40 · 29110.2165/00003495-199040020-00008 ↗
37. Hoehns J. D. · J. Clin. Pharm. · 1993 · 12 · 881
38. Burges R. A. · J. Hum. Hypertens. · 1991 · 5 · 49
39. Murdoch D. · Drugs · 1991 · 41 · 47810.2165/00003495-199141030-00009 ↗
40. Sheth A. R. · Cryst. Growth Des. · 2004 · 4 · 109110.1021/cg049876y ↗
41. Boldyrev V. V. · J. Mat. Sci. · 2004 · 39 · 511710.1023/B:JMSC.0000039193.69784.1d ↗
42. Banerjee R. · Angew. Chem., Int. Ed. · 2005 · 44 · 251510.1002/anie.200462967 ↗
43. Kinbara, K.; Saigo, K. InTopics in Stereochemistry; Denmark, S. E., Ed.; Wiley: New York, 2003; pp 207−265.10.1002/0471224499.ch4 ↗
44. Sivalakshmidevi A. · Acta Crystallogr., Sect. E · 2002 · 58 · 107210.1107/S160053680201588X ↗
45. Vega D. · Acta Crystallogr., Sect. E · 2000 · 56 · 1009
46. Rao S. M.
47. (a) Zaworotko, M. J.; Moulton, B.; Rodriguez-Hornedo, N. International publication no., WO 03/074474 A2, 12/09/2003.
48. (b) Almarsson, Ö.; Zaworotko, M. J. International publication no., WO. 2004/078161 A1, (16/09/2004).
49. (c) Childs, S. L. International publication no., WO 2004/064762 A2, 05/08/2004.